We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
A team of researchers at the Tokyo University of Science (TUS), Japan, have achieved success in the intranasal delivery of the anti-depressant drug glucagon-like peptide 2 (GLP-2) in a mouse model of depression.